Share
1,345 Posts.
lightbulb Created with Sketch. 141
clock Created with Sketch. 24/04/22
20:10
Share
Originally posted by Rich&Poor:
↑
ASX RELEASE Simcere will assume responsibility for the development, registration, and Kazia will also receive ASX RELEASE The GBM AGILE pivotal study in glioblastoma commenced recruitment to the paxalisib arm recruitment to the paxalisib arm is ongoing in the United Statesand the study is expected to open in Europe and China during Q2 or Q3 of IMO expect Simcere contingent milestone payments of up to US$ 281 million (at present AU$ 388 million) for glioblastoma, based on progress in China of the GBM AGILE study arm of paxalisib. A final payment based on Simcere receiving a paxalisib drug marketing approval for glioblastoma treatment from the Chinese regulators.
Expand
these posts have reiterated my thoughts that we might get a milestone payment from Simcere soon for the completion of the P2 study and or the commencement of the Chinese arm of GBM Agile. It would be prudent management by JG to have $ coming in at different stages in order to alleviate the need for CR (which I'm sure he'd be aware of when he'd need the $)
